4HF Biotec runs programs to identify new small molecules that may represent future treatments. Wide varieties of compounds with known or putative antitumor activities are selected and engaged in testing series with large sets of tumors. The use of our proprietary platform and databases allows to optimally determine the best indications, drug performance and predictive biomarkers.

​

Today, hundreds of potential new anticancer drugs with various mechanisms of actions have been tested. Our best candidates are currently evaluated in various drug combinations in a large variety of tumor models in vitro and in vivo to reveal synergism and new treatment options.